Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evofem Biosciences, Inc.EVFM · Entity 8607 | Chief Medical Officer | May 20, 2021 | May 21, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evofem Biosciences, Inc.
Report date May 20, 2021 · Filed May 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 273,390 |
Reported balance
After 2021-05-20 transaction · row 1
1 source rowRow 1 · 2021-05-20 · Tax withholding · Disposed 42,061 · Balance 273,390 F1: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 20, 2021. No shares were sold in connection with this transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 20, 2021. No shares were sold in connection with this transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2021 Filed May 21, 2021 20:26 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 42,061 | $0.86 | $36,172.46 |
DisclosureSEC source: 0001618835-21-000135 · wf-form4_162162876295987.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,390 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 20, 2021. No shares were sold in connection with this transaction. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:54 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001618835-21-000007 · wf-form4_161240003886283.xml · derivative · entry 2 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-02-03 F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 3, 2021. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:54 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-21-000007 · wf-form4_161240003886283.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,451 F1 · shares: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2021. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 21:43 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 31,548 | $3.31 | $104,423.88 |
DisclosureSEC source: 0001618835-20-000188 · wf-form4_159165256285979.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,451 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on June 5, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:16 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 39,435 | $4.99 | $196,780.65 |
DisclosureSEC source: 0001618835-20-000157 · wf-form4_159052777118613.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,999 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 22, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 06, 2020 Filed May 8, 2020 16:31 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 7,792 | $5.24 | $40,830.08 |
DisclosureSEC source: 0001618835-20-000114 · wf-form4_158895549907652.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,434 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 6, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 01, 2020 Filed May 2, 2020 00:12 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | SaleCommon Stock | 1,000 | $4.75 | $4,750.00 |
DisclosureSEC source: 0001618835-20-000096 · wf-form4_158837835074185.xml · nonDerivative · entry 2 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,226 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 25, 2019. Read SEC document |
| April 30, 2020 Filed May 2, 2020 00:12 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | SaleCommon Stock | 1,000 | $4.66 | $4,660.00 |
DisclosureSEC source: 0001618835-20-000096 · wf-form4_158837835074185.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,226 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 25, 2019. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 19:10 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | SaleCommon Stock | 1,000 | $7.00 | $7,000.00 |
DisclosureSEC source: 0001618835-20-000028 · wf-form4_158231222323693.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,226 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 25, 2019. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:32 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001618835-20-000019 · wf-form4_158111112862260.xml · derivative · entry 3 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-05 F5 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 5, 2020 Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:32 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-20-000019 · wf-form4_158111112862260.xml · nonDerivative · entry 2 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,226 F4 · shares: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:32 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 3,688 | $5.21 | $19,214.48 |
DisclosureSEC source: 0001618835-20-000019 · wf-form4_158111112862260.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,226 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Evofem Biosciences, Inc. 2019 Employee Stock Purchase Plan (2019 ESPP), for the ESPP purchase period of June 17, 2019 through December 13,2019. This transaction is also exempt under Rule 16b-3(c). F2 · date: The reporting person is voluntarily reporting this transaction as of February 5, 2020, but the actual transaction took place on December 13, 2020, the last trading day of the purchase period under the 2019 ESPP. F3 · shares: In accordance with the 2019 ESPP, these shares were purchased based on 85% of the closing stock price on December 13, 2019, the last trading day of the purchase period. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 22:34 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | SaleCommon Stock | 1,000 | $7.35 | $7,350.00 |
DisclosureSEC source: 0001618835-19-000214 · wf-form4_157549882846938.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,538 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 25, 2019. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 22:14 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 5,187 | $6.22 | $32,263.14 |
DisclosureSEC source: 0001618835-19-000202 · wf-form4_157480646585981.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,538 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on November 25, 2019. No shares were sold in connection with this transaction. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 01:18 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 5,187 | $5.74 | $29,773.38 |
DisclosureSEC source: 0001618835-19-000185 · wf-form4_157438551205670.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,725 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on November 20, 2019. No shares were sold in connection with this transaction. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 22:36 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 864 | $5.13 | $4,432.32 |
DisclosureSEC source: 0001618835-19-000155 · wf-form4_156685898995521.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,912 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on August 22, 2019. No shares were sold in connection with this transaction. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 20:39 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 5,187 | $6.36 | $32,989.32 |
DisclosureSEC source: 0001618835-19-000126 · wf-form4_156037195682205.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,776 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on June 10, 2019. No shares were sold in connection with this transaction. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:41 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 1,022 | $3.55 | $3,628.10 |
DisclosureSEC source: 0001618835-19-000048 · wf-form4_155433127743033.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,963 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on April 1, 2019. No shares were sold in connection with this transaction. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 21:10 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-19-000018 · wf-form4_155130180168119.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,985 F1 · shares: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2019. Read SEC document |
| November 28, 2018 Filed Nov 29, 2018 23:10 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock · Derivative | 0 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001618835-18-000116 · wf-form4_154353298929720.xml · derivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 0 shares Expires 2028-11-28 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from November 28, 2018. Read SEC document |
| November 28, 2018 Filed Dec 3, 2018 17:49 UTC Amendment | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock · Derivative | 100,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001618835-18-000125 · wf-form4a_154385936577343.xml · derivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-11-28 F1 · shares: The original Form 4, filed on November 29, 2018, is being amended to update the number of shares reported in Column 5(A) and Column 7 of Table II. F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from November 28, 2018. F1 · derivative.underlying_shares: The original Form 4, filed on November 29, 2018, is being amended to update the number of shares reported in Column 5(A) and Column 7 of Table II. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 22:25 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 3,000 | $2.24 | $6,720.00 |
DisclosureSEC source: 0001618835-18-000088 · wf-form4_153480391131224.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,985 Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:16 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock · Derivative | 98,800 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001618835-18-000074 · wf-form4_153324099080945.xml · derivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,800 Underlying: Common Stock · 98,800 shares Expires 2028-07-31 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 20:54 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 4,748 | $2.46 | $11,680.08 |
DisclosureSEC source: 0001618835-18-000045 · wf-form4_153065127305105.xml · nonDerivative · entry 2 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,985 F2 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on July 2, 2018. No shares were sold in connection with this transaction. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 20:54 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 13,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000045 · wf-form4_153065127305105.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,733 F1 · shares: The restricted stock awards vested in full on July 2, 2018. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 21:16 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 260,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019635 · doc4.xml · derivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: Dr. Culwell acquired a vested interest in 66.67% of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018 (the "Vesting Start Date"). The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from the Vesting Start Date. The option was awarded in connection with Dr. Culwell's service as Chief Medical Officer. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 22:01 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock Option (right to buy) · Derivative | 7,699 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004295 · doc4.xml · derivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,699 Underlying: Common Stock · 7,699 shares Expires 2026-09-28 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F3 · derivative.exercise_date: Dr. Culwell acquired a vested interest in twenty-five percent (25%) of the shares of common stock exercisable pursuant to the option effective as of September 28, 2016 (the "Vesting Start Date"). The remaining shares shall vest in a series of thirty-six (36) successive equal monthly installments on the monthly anniversary of the Vesting Start Date, such that all shares of common stock of Issuer exercisable pursuant to the option shall be fully vested on September 28, 2019, subject to Dr. Culwell's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.